Sarita Said-Said, MD
Neurology · Moscow, IDNPI 1922449453
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,895 of the $8,087 with a category attached, or 72.9%. Amgen accounts for 76.6% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $6,421 and has fallen 97.6% since, to $157 in 2025.
Across 115 payments — averaging $70.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$6K
- AbbVie$590
- Bristol Myers Squibb$430
- Biogen$228
- CSL Behring$90
- Argenx US, Inc.$74
- plus $480 from 15 others
What the payments were for
- Consulting fees$5,89573%
- Food & beverage$2,19327%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $6,195 |
| AbbVie | 51 | $590 |
| Bristol Myers Squibb | 25 | $430 |
| Biogen | 7 | $228 |
| CSL Behring | 1 | $90 |
| Argenx US, Inc. | 4 | $74 |
| Pfizer | 4 | $73 |
| Grifols Shared Services North America, Inc. | 1 | $58 |
| AstraZeneca | 3 | $53 |
| Medtronic | 1 | $53 |
| Neurocrine Biosciences, Inc. | 3 | $48 |
| EMD Serono, Inc. | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| GE HealthCare | 1 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,087 in reported general payments places this provider in the 75th percentile of 59 neurology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvrysdiRisdiplam | 16 | $433,015 |
| KeveyisDichlorphenamide | 11 | $381,475 |
| CopaxoneGlatiramer Acetate | 12 | $65,081 |
| Nurtec OdtRimegepant Sulfate | 32 | $44,175 |
| Aimovig AutoinjectorErenumab-Aooe | 42 | $30,322 |
| QuliptaAtogepant | 29 | $29,235 |
| UbrelvyUbrogepant | 21 | $20,574 |
| BriviactBrivaracetam | 13 | $17,602 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 14 | $9,992 |
| Acetazolamide | 37 | $5,809 |
| TrexallMethotrexate Sodium | 22 | $5,131 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 177 | $4,672 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 110 | $2,067 |
| Entacapone | 39 | $1,550 |
| Pregabalin | 66 | $1,505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Xeris Pharmaceuticals, Inc.Keveyis | $15 | $381,47511 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $20 | $65,08112 claims |
| AbbVieQulipta, Ubrelvy | $590 | $49,80950 claims |
| PfizerNurtec Odt | $73 | $44,17532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 59 neurology providers in Idaho.
Other neurology in Moscow
- Bradford TalcottIdaho Falls$252K
- Lawrence GreenNampa$193K
- Stephen VincentIdaho Falls$156K
- Nina BozinovCoeur D Alene$76K
- Angela PanaCoeur D Alene$37K
- Erich GarlandIdaho Falls$33K
- Sergei KashirnyBoise$20K
- Richard HammondTwin Falls$16K
- Kylie AbeMeridian$16K
- John SteffensTwin Falls$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.